Erasca, Inc. (ERAS)
NASDAQ: ERAS · IEX Real-Time Price · USD
1.890
+0.010 (0.53%)
Apr 26, 2024, 4:00 PM EDT - Market closed
Erasca Market Cap
Erasca has a market cap or net worth of $286.32 million as of April 26, 2024. Its market cap has decreased by -33.16% in one year.
Market Cap
286.32M
Enterprise Value
28.67M
1-Year Change
-33.16%
Ranking
Category
Stock Price
$1.89
Market Cap Chart
Since the IPO on July 16, 2021, Erasca's market cap has decreased from $1.86B to $286.32M, a decrease of -84.59%. That is a compound annual growth rate of -48.99%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 25, 2024 | 284.80M | - |
| Apr 24, 2024 | 284.80M | -2.60% |
| Apr 23, 2024 | 292.40M | 4.32% |
| Apr 22, 2024 | 280.30M | 3.36% |
| Apr 19, 2024 | 271.20M | - |
| Apr 18, 2024 | 271.20M | -2.69% |
| Apr 17, 2024 | 278.70M | -4.69% |
| Apr 16, 2024 | 292.40M | -3.50% |
| Apr 15, 2024 | 303.00M | -5.22% |
| Apr 12, 2024 | 319.70M | -7.84% |
| Apr 11, 2024 | 346.90M | 3.15% |
| Apr 10, 2024 | 336.30M | -1.78% |
| Apr 9, 2024 | 342.40M | 0.91% |
| Apr 8, 2024 | 339.30M | 6.66% |
| Apr 5, 2024 | 318.10M | 0.47% |
| Apr 4, 2024 | 316.60M | -3.68% |
| Apr 3, 2024 | 328.70M | 0.92% |
| Apr 2, 2024 | 325.70M | -0.46% |
| Apr 1, 2024 | 327.20M | 4.84% |
| Mar 28, 2024 | 312.10M | - |
| Mar 27, 2024 | 312.10M | 4.31% |
| Mar 26, 2024 | 299.20M | -4.35% |
| Mar 25, 2024 | 312.80M | -3.69% |
| Mar 22, 2024 | 324.80M | - |
| Mar 21, 2024 | 324.80M | 2.36% |
View and export this data all the way back to 2021.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| TriSalus Life Sciences | 298.88M |
| Kamada | 298.87M |
| Nautilus Biotechnology | 295.23M |
| XOMA Corporation | 294.83M |
| GeneDx Holdings | 291.02M |
| CorMedix | 284.47M |
| Verrica Pharmaceuticals | 282.09M |
| AxoGen | 281.70M |